<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25235">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778243</url>
  </required_header>
  <id_info>
    <org_study_id>2014/01</org_study_id>
    <secondary_id>2014-A00706-41</secondary_id>
    <nct_id>NCT02778243</nct_id>
  </id_info>
  <brief_title>Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level</brief_title>
  <acronym>STERPROSER</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients followed in the Foch Hospital Urology Department (Suresnes): Patients justifying a
      prostatectomy.

        -  Patients justifying prostatectomy together with the bladder (radical cystectomy for
           bladder cancer).

        -  Patients with benign prostate hyperplasia who justified a prostatectomy. Compare serum
           sexual steroid concentrations and intra-tissue on healthy prostates and prostate
           adenoma, assess concentrations intra-tissue sex steroids on cancer metastasis prostate
           specific blood sample under study (30mL) will be performed preoperatively in Patients
           followed in Foch Hospital Urology Department (Suresnes), and a Removal of a fragment of
           prostate tissue or metastasis will be analyze.

      Aim is to compare serum concentrations of sexual steroids and intra-tissue on healthy
      prostates and prostate adenomas compared to concentrations measured in patients operated for
      prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Steroids concentration will be determined using Gas chromatography-mass spectrometry. The
      analyzed steroids are :

      FSH :Mul/ml LH: mUI/ml SHBG: µg/ml BT: ng/ml TT: ng/ml DHT: ng/ml DHEA: ng/ml D5: ng/ml D4:
      ng/ml E1: pg/ml E2 : pg/ml DHEA-S : µg/dl
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentrations of sexual steroids and intra-tissue on healthy prostates</measure>
    <time_frame>30 minutes</time_frame>
    <description>A bio-informatical analysis will be performed to compare steroids concentrations profiles in both arms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Urinary Bladder Neoplasms</condition>
  <condition>Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Bladder cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign prostate hyperplasia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>▪ Patients with benign prostate hyperplasia who justified a prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>steroids concentrations determination</intervention_name>
    <arm_group_label>Bladder cancer</arm_group_label>
    <arm_group_label>benign prostate hyperplasia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged over 18 years

          -  Surgical indication justifying protatique prostatectomy, or complete
             prostatocystectomie, or removal of a metastasis of prostate cancer.

          -  Patients affiliated to a social security scheme or benefiting from such a regime.

          -  Patients who have given their consent to participate in writing

        Exclusion Criteria:

          -  Patient received local therapy or hormonal treatment (LHRH analogue, therapy blocking
             androgen receptors) before surgery.

          -  Treatment reductase inhibitors 5ARI ongoing or stopped for less than 3 months before
             the intervention.

          -  Patient included in another clinical trial inconsistent with the conduct of this
             research.

          -  Patient receiving treatment that could interfere with hormone levels (Prednisone,
             Ketoconazole, Abiraterone, Finasteride, Dutasteride).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Botto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urologie Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henry Botto, PhD</last_name>
    <phone>33(0)612428613</phone>
    <email>henry.botto@orange.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Botto, PhD</last_name>
      <phone>33(0)612428613</phone>
      <email>henry.botto@orange.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>May 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
